Management of Positional Purple Toe Syndrome

Introduction to Purple Toe Syndrome

• Purple toe syndrome is a rare, non-hemorrhagic complication typically associated with warfarin therapy, characterized by sudden appearance of painful purple lesions on toes that blanch with pressure, according to the American College of Chest Physicians 1

Diagnosis and Evaluation

• The American College of Cardiology recommends confirming adequate arterial circulation, as presence of good pulses suggests adequate large vessel circulation, and improvement with wiggling indicates reversible ischemia 1
• Medication review should include checking if the patient is on warfarin therapy and reviewing the duration of warfarin use, typically occurring 3-8 weeks after initiation, as suggested by the American College of Chest Physicians 1
• Evaluation for other causes should include assessing for signs of arterial insufficiency despite good pulses, checking for foot deformities or ill-fitting footwear, and evaluating for diabetes and neuropathy, as recommended by the American Diabetes Association 2
• A comprehensive diagnostic workup including ankle-brachial index (ABI) measurement, toe-brachial index (TBI), and duplex ultrasound is recommended for patients with suspected PAD and CVI, followed by targeted treatment addressing both conditions, as suggested by the American College of Cardiology 3
• Vascular review of symptoms should assess walking impairment, claudication, ischemic rest pain, presence of non-healing wounds, edema, skin changes, and varicosities 3
• Ankle-Brachial Index (ABI) is the first-line test, with results interpreted as:
• For noncompressible arteries (ABI >1.40), alternative methods such as toe-brachial index (TBI), Doppler waveform analysis, or pulse volume recording should be used, with normal TBI: >0.70 and abnormal TBI: ≤0.70 3, 4, 5

Treatment and Management

• The American College of Cardiology recommends switching to alternative anticoagulation if continued anticoagulation is required, such as direct oral anticoagulants (DOACs) or low molecular weight heparin (LMWH) 3
• Footwear assessment should ensure proper fitting shoes and consider special footwear or orthoses if foot deformities are present, as suggested by the American Diabetes Association 2
• Vascular evaluation, including arterial duplex ultrasound, should be considered if symptoms persist, as recommended by the American College of Cardiology 3
• The American Heart Association recommends distinguishing from acute limb ischemia, which is a medical emergency requiring immediate intervention 6
• A supervised exercise program is the cornerstone treatment for PAD with claudication, with a frequency of at least 3 times weekly, duration of ≥30 minutes per session, and program length of ≥12 weeks, as recommended by the American Heart Association and the American College of Cardiology 6, 5, 4
• Statin therapy is recommended for all PAD patients, with a target LDL-C reduction ≥50% from baseline and a goal <55 mg/dL 7, 8, 4
• Antiplatelet therapy, such as aspirin (75-160 mg daily) or clopidogrel (75 mg daily), is recommended for symptomatic PAD, with consideration of low-dose rivaroxaban (2.5 mg twice daily) plus aspirin for high-risk patients, as suggested by the American College of Cardiology 7, 4
• Blood pressure control is essential, with a target <140/90 mmHg for non-diabetics and <130/80 mmHg for diabetics, as recommended by the American College of Cardiology 8, 5
• Tight glycemic control (HbA1c <7%) is recommended for patients with diabetes, according to the American College of Cardiology 9, 4
• Cilostazol 100 mg twice daily and pentoxifylline 400 mg three times daily may be considered to improve walking distance and quality of life 4
• Smoking cessation is critical for both PAD and CVI management
• Compression therapy is recommended when ABI ≥0.5, using progressive elastic compression stockings, with monitoring for skin changes or discomfort, as suggested by the American College of Cardiology 6
• Meticulous foot care is essential, including daily foot inspection, appropriate footwear, and prompt treatment of skin lesions and ulcerations, as recommended by the American Heart Association and the American College of Cardiology 6, 9

Follow-up and Monitoring

• Regular vascular assessment, including pulse examination and foot inspection, should be performed if symptoms persist, as recommended by the American College of Cardiology 3
• Long-term monitoring is necessary for patients with identified vascular disease or those who experienced warfarin-induced purple toe syndrome, as suggested by the American College of Chest Physicians 1
• Regular follow-up at least annually is necessary, with assessment of clinical and functional status, medication adherence, limb symptoms, and cardiovascular risk factors, as suggested by the American College of Cardiology 6, 4, 3
• Duplex ultrasound (DUS) assessment should be performed as needed, with ABI and arterial duplex ultrasound within 1-3 months post-revascularization procedure, and repeat at 6 and 12 months, then annually 4, 3

Revascularization and Advanced Management

• Revascularization may be considered for functionally limiting claudication with inadequate response to medical therapy or chronic limb-threatening ischemia, with an approach based on lesion characteristics, as recommended by the American College of Cardiology 6, 3, 4, 5
• Endovascular-first approach is recommended for functionally limiting claudication with inadequate response to medical therapy, and urgent revascularization is indicated for limb salvage, as suggested by the American College of Cardiology 3, 4, 5
• Endovascular-first strategy is recommended for short (<5 cm) aorto-iliac occlusive lesions and short (<25 cm) femoro-popliteal occlusive lesions 5
• Bypass surgery using autologous vein is preferred for long (≥25 cm) femoro-popliteal occlusive lesions or infra-popliteal occlusive lesions 5
• Beta-blockers are not contraindicated in PAD, according to the American College of Cardiology 8, 9
• Delaying treatment of foot infections in PAD patients increases amputation risk, as warned by the American Heart Association 6
• Antiplatelet therapy is not routinely recommended for asymptomatic PAD without clinically relevant atherosclerotic cardiovascular disease 4